Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors.
admissions
checkpoint inhibitors
genomic alterations
immune-related adverse events (irAEs)
lung cancer
next-generation sequencing
overall survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 May 2021
28 May 2021
Historique:
received:
30
04
2021
revised:
22
05
2021
accepted:
25
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Lung cancer patients undergoing systemic treatment with immune checkpoint inhibitors (ICIs) can lead to severe immune-related adverse events (irAEs) that may warrant immediate hospitalization. Patients with thoracic malignancies hospitalized at City of Hope while undergoing treatment with ICIs were identified. Pathology and available next-generation sequencing (NGS) data, including the programmed death-ligand 1 (PD-L1) status and clinical information, including hospitalizations, invasive procedures, and the occurrence of irAEs, were collected. Unpaired T-tests, Chi-square/Fisher's exact test, and logistic regression were used to analyze our cohort. The overall survival (OS) was calculated and compared using univariate and multivariate COX models. Ninety patients with stage IV lung cancer were admitted after ICI treatment. Of those patients, 28 (31.1%) had documented irAEs. Genomic analyses showed an enrichment of
Identifiants
pubmed: 34071259
pii: cancers13112653
doi: 10.3390/cancers13112653
pmc: PMC8198372
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30CA033572
Pays : United States
Organisme : NCI NIH HHS
ID : U54CA209978
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA247471
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA218545
Pays : United States
Références
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
J Exp Clin Cancer Res. 2020 Dec 14;39(1):284
pubmed: 33317597
Thorac Cancer. 2020 Jul;11(7):1955-1962
pubmed: 32468726
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
J Cancer Res Clin Oncol. 2019 Jun;145(6):1613-1623
pubmed: 30911841
Am J Clin Oncol. 2021 Mar 1;44(3):114-120
pubmed: 33417323
Clin Lung Cancer. 2019 May;20(3):201-207
pubmed: 30442524
Oncologist. 2021 Jan;26(1):49-55
pubmed: 33044765
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
Oncotarget. 2016 Oct 18;7(42):68721-68733
pubmed: 27626682
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Front Immunol. 2019 May 21;10:1113
pubmed: 31164891
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
JAMA Oncol. 2019 Oct 1;5(10):1411-1420
pubmed: 31343665
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
J Geriatr Oncol. 2019 May;10(3):411-414
pubmed: 30104155
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
Cancer Cell. 2014 May 12;25(5):652-65
pubmed: 24794707
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Genomics. 2000 Oct 15;69(2):271-4
pubmed: 11031110
Oncotarget. 2020 Jan 07;11(1):1-14
pubmed: 32002119
Ann Oncol. 2019 May 1;30(5):839-844
pubmed: 30847464
Ann Oncol. 2018 Oct 1;29(10):2085-2091
pubmed: 30165371
EMBO Rep. 2019 Mar;20(3):
pubmed: 30665945
Lung Cancer. 2018 Jan;115:71-74
pubmed: 29290265
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289
pubmed: 30865922
Cancer Chemother Pharmacol. 2019 Oct;84(4):873-880
pubmed: 31444618
Lung Cancer. 2020 Aug;146:174-181
pubmed: 32554069
J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485
pubmed: 30506406
Int J Cancer. 2019 Aug 1;145(3):639-648
pubmed: 30653255
Nat Med. 2017 May 5;23(5):540-547
pubmed: 28475571
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Clin Lung Cancer. 2019 Jan;20(1):e97-e106
pubmed: 30337270
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Semin Oncol. 2018 Jun;45(3):156-163
pubmed: 30348532
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Clin Cancer Res. 2020 Aug 1;26(15):4135-4142
pubmed: 32332016
J Clin Oncol. 2012 Jul 20;30(21):2691-7
pubmed: 22614989
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407